CTNI-33. DEBIO1347, AN ORAL FGFR INHIBITOR: RESULTS FROM A SINGLE CENTER STUDY IN PEDIATRIC PATIENTS WITH RECURRENT/REFRACTORY FGFR ALTERED GLIOMAS

BACKGROUND: Oncogenic driver alterations in fibroblast growth factor receptors (FGFRs) are present in a subset of pediatric gliomas. Debio1347 is an orally available, highly selective FGFR 1–3 inhibitor with a favorable safety profile and encouraging preliminary clinical activity in an adult phase 1...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neuro Oncol
Asıl Yazarlar: Farouk Sait, Sameer, Rosenblum, Marc, Bale, Tejus, Haque, Sofia, Gilheeney, Stephen, Spatz, Krisoula, Prince, Daniel, Ibanez, Katarzyna, Dunkel, Ira, Karajannis, Matthias
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2020
Konular:
Clinical Trials: Non-Immunologic
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651617/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.200
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller